Platforms

Driving Progress Through Technology: CD BioGlyco’s Platforms Lead the Way

CD BioGlyco is a pioneering biotechnology firm that has engineered and refined an array of research platforms focused on glycobiology. Glycobiology is defined as the study of the structure, biosynthesis, and biological functions of glycans and saccharide conjugates (including glycoproteins, glycolipids, proteoglycans, etc.), as well as protein-glycan interactions. Glycogenomics, glycoproteomics, glycomics, and geoinformatics help us better understand the various cellular events involved in saccharides and the role of glycans in diseases. In the production of biological agents, glycans also affect the therapeutic properties of protein drugs and their immune responses.

Fig.1 Carbohydrate generation and glycan microarray. Fig.1 Influence of glycans and glycan-binding proteins in death receptor signaling and function. (Zol-Hanlon & Schumann, 2020)

To facilitate clients in exploring the multifaceted dimensions of glycobiology research, CD BioGlyco endeavors to provide extensive platforms. These diverse platforms have made available an array of sophisticated analytical methodologies and data analysis techniques tailored for glycobiological investigations. Our goal is to offer a wide range of services, enabling clients to explore the intricate world of glycobiology with thoroughness and precision. Our first-class technology platforms and experienced scientists provide clients with high-precision, high-efficiency, and high-throughput services.

Platforms at CD BioGlyco

Glyco™ Synthesis Platform

CD BioGlyco focuses on developing different synthesis methods to provide clients with customized synthesis services of various glyco- and glycoconjugates by the Glyco™ synthesis platform. We offer various approaches, including chemical, enzymatic, and chemoenzymatic approaches, to obtain these substances. This platform is important for studying the structure and function of sugars and glycoconjugates and developing new biological drugs.

Glycomics Platform

CD BioGlyco has accumulated rich experience in the glycobiology field and developed an efficient glycomics platform to provide our clients with scientific help. This platform provides a variety of services tailored for investigating glycobiology, such as glycan liberation, glycan isolation and purification, glycomic profiling, and quantitative glycomic analysis. We also provide valuable glycan derivation services to support research in glycobiology.

Glycoproteomics Platform

By using our glycoproteomics platform, we provide clients with comprehensive services of glycoproteins. Our enrichment approaches help reduce the impact of abundant non-glycoproteins on glycosylation analysis, allowing us to obtain glycoproteins that are more concentrated. Customized workflows are provided for quantification, site occupancy determination, and structural analysis, contributing to the comprehensive analysis of glycoproteins.

Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform

This platform is meticulously oriented towards glycosylation site specificity. It has consistently prioritized the creation of ADCs that target distinct glycosylation sites, enhancing the precision and efficacy of therapeutic applications. We provide three distinct conjugation strategies for binding payloads to these sites: glycan oxidation, glycan enzymatic modification, and glycoengineering.

Carbohydrate-based Glycomedicine Development Platform

CD BioGlyco is confident in our carbohydrate-based glycomedicine development platform. Our research team possesses a wealth of expertise and is adept at utilizing diverse sources of carbohydrates. By this platform, we provide diverse carbohydrate-based research, including anticoagulation, anti-tumor, anti-diabetic, antibacterial, antiviral, and antiparasitic purposes.

Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)

CD BioGlyco has an advanced platform, MOPCGM, to help clients explore the field of cancer glucose metabolism. Our MOPCGM is a state-of-the-art profiling platform that utilizes cutting-edge technologies, including fluxomics, genomics, proteomics, and metabolomics, to quantify and functionally analyze glucose metabolites throughout various stages of cancer progression - from cell to animal level.

Glycoengineering Platform

There are various services that include in vitro glycoengineering (IVGE), cell line glycoengineering, and sialic acid glycoengineering by using the glycoengineering platform. We provide clients with diverse glycoengineered expression systems to customize one-stop services for glycoengineered antibodies. Our platform also offers glycoengineering services for glycoprotein expression and protein glycoengineering.

Glycobiology Microarray Platform

CD BioGlyco provides clients with a glycobiology microarray platform to study the functions and mechanisms of glycans in organisms. We offer a wide range of services to accelerate glycobiology research and discovery, such as custom microarray printing service, and glycomics profiling with microarray. This platform facilitates swift, high-throughput, and precise assays for a variety of carbohydrate-related substances.

Glyco™ Vaccine Development Platform

CD BioGlyco has developed a glyco-based vaccine development platform to provide clients with better solutions for the design, production, and optimization of vaccines. By using advanced methodologies, we offer various solutions in glyco-based vaccine development and research, including glycoprotein-based vaccines, glycopeptide-based vaccines, carbohydrate-based vaccines, and carbohydrate-based vaccine adjuvants.

Glycogenomics Platform

We are at the forefront of glycogenomics advancements, enabling the establishment of a top-tier platform. Through our glycogenomics platform, we offer clients comprehensive glycogene editing, delivery, and expression profiling services, as well as an exceptional cancer glycogene discovery service. Our platform integrates glycogene editing capabilities with the identification of disease-associated glycogenes, providing clients with a scientific one-stop solution.

Glycan Display Platform

Our glycan display platform is an innovative tool for exploring, analyzing, and manipulating glycans with precision and flexibility. Our platform includes a range of state-of-the-art glycan display technologies, such as traditional, cell-based, neoglycolipid (NGL), liquid (LiGA), glyco-phage, and de novo methods, to meet clients' needs. We help clients drive glycobiology research with our glycan display platform.

GlycoNano™ Platform

At CD BioGlyco, our GlycoNano™ Platform pioneers glyconanotechnology to engineer precision glyconanoparticles for drug delivery, diagnostics, and 3D bioprinting. Using advanced synthesis (CuAAC, hydrogen bonding) and characterization, we offer production, testing, biosensors, and tissue-specific bioinks, accelerating R&D from concept to market solutions.

At CD BioGlyco, we also have a range of ready-made Products for selection. These products greatly assist clients in their various glycobiology research. Our products are distinguished by their outstanding quality, supported by strong guarantees, and are adaptable to fulfill the requirements of multiple industries. Our products encompass, but are not limited to:

Carbohydrates

Enzymes

Glycoconjugates

Glycosylation Related Products

Carbohydrate Antigen

Glycobiology Arrays

Nucleosides and Nucleotides

Natural Products

Lectin Products

Assay Kits

Bioactive Compounds

Inhibitors

On the whole, CD BioGlyco has provided a large number of advanced analysis techniques and data analysis tools for glycobiology research. Glyco™ synthesis platform helps to synthesize a variety of glycoconjugates. Glycomics results are combined with other "omics data sets" to gain a deeper understanding and insight into the nature of glycosylation in complex cellular processes. Through our glycoproteomics platform, we identify, classify, quantify, and characterize glycoproteins. The glycobiology microarray platform is widely used to analyze the entire glycogen group and glycosylase under pathological conditions. Glyco™ vaccine development helps accelerate vaccine development and preclinical research. The glycoengineering platform is an important strategy for improving the safety, consistency, and reduced immunogenicity of biological drugs.

Publication Data

Technology: Solid-phase synthesis, Chemical-enzymatic synthesis, Catch and release strategy, Glycan microarray

Journal: Frontiers in Chemistry

IF: 5.5

Published: 2020

Results: This scholarly review delves into recent strides in chemo-enzymatic methodologies aimed at fabricating precisely structured N-glycans, pivotal for comprehending protein functionalities and fostering innovative therapeutic avenues. The authors describe advancements in substrate formulation, glycosyltransferase characterization, and the synthesis of high-mannose, hybrid, and complex N-glycan varieties, underscoring the synergistic benefits of amalgamating chemical and enzymatic approaches to realize efficient and precise N-glycan synthesis. It also probes emergent prospects such as automated synthesis technologies, underscoring their potential applications in refining glycoprotein formulation and advancing biomarker delineation. Ultimately, the authors describe these methodologies’ potential to catalyze paradigm shifts in N-glycan exploration and therapeutic interventions.

Fig.2 Enzymes for making high-mannose, hybrid, and complex N-glycans. Fig.2 Typical glycosyltransferases and glycosidases for the enzymatic synthesis of high-mannose, hybrid, and complex-type N-glycans. (Chao, et al., 2020)

Applications

Glyco™ synthesis platform can be used to synthesize complex carbohydrate molecules for use in glycobiology, materials science, drug development, and other fields.
Glycomics platform is applied to analyze structures and functions of complex carbohydrates in therapeutic and diagnostic research of cancer, infectious diseases, and metabolic disorders.
Glycoproteomics platform will be utilized to identify, quantify, and characterize glycoproteins from biological samples to support the development of new therapies.
Glycosylation site-specific ADC development platform can be employed for research and development of targeted and effective anti-cancer drugs.
Carbohydrate-based glycomedicine development platform is useful for discovering and developing carbohydrate-based therapeutic drugs for the inhibition of inflammatory and autoimmune diseases, cancer, and viral infections.
Through our platform for the production of ingredients, we help clients to improve nutritional and functional characteristics.
Our MOPCGM can be used to identify and analyze metabolic abnormalities in cancer cells to support the new therapeutic development.
The glycoengineering platform is used to modify proteins, cells, and tissues for the research of enhancing therapeutic efficacy and reducing immunogenicity.
The glycobiology microarray platform can be used for high-throughput analysis of glycan-protein interactions for the development of new therapies and diagnostic tools.
Glyco™ vaccine development platform can be employed to discover and develop carbohydrate-based vaccines for the prevention of infectious diseases and cancer.
Glycogenomics platform is useful to identify and characterize genes involved in glycogen metabolism for the development of new therapies for glycogen storage diseases.

Advantages

CD BioGlyco's diverse glyco-biotechnology platforms support advancements in life sciences, pharmaceutical research, and vaccine development with innovative solutions.
CD BioGlyco possesses efficient and user-friendly glyco-analysis techniques to reduce experimental time and improve research efficiency and accuracy.
CD BioGlyco has extensive capabilities in glycan synthesis and modification for producing high-quality glycan that has various applications in drug discovery, biological research, and other industries.
CD BioGlyco supports large-scale data analysis and storage, facilitating ongoing scientific research and development.
CD BioGlyco has strong interdisciplinary expertise and collaborations, promoting the cross-pollination of ideas and solutions in glyco-related research areas.
CD BioGlyco is committed to innovation and continuous improvement and stays up-to-date with the latest technological advancements to meet the evolving needs of clients and the scientific community.

Frequently Asked Questions

What role does glycosylation play in living organisms?

In the post-genomic era, researchers have identified four fundamental substances in all organisms: nucleic acids, proteins, lipids, and glycans. New research areas such as genomics, proteomics, lipidomics, and metabolomics have appeared that correspond to each substance. While it’s estimated that the human genome encodes 20,000 to 25,000 proteins, the entire proteome actually comprises over a million proteins. Posttranslational modifications of proteins which lead to increased proteome complexity are one reason for this difference. Glycosylation, in particular, plays a crucial role, with its abnormalities linked to diseases such as cancer, diabetes, and neurodegeneration.

CD BioGlyco is a global biotechnology company that has accomplished several successful glycobiology projects. Firmly anchored in a steadfast commitment to excellence, CD BioGlyco combines profound expertise with state-of-the-art platforms, fostering unparalleled confidence in its capacity to meet the most exacting demands. Spanning a spectrum of integrated glyco-biotechnology platforms, its cadre of researchers is perpetually pioneers within life sciences, pharmaceuticals, and allied sectors. Esteemed for delivering premium solutions, we have become a good partnership grounded in trust and reliability. CD BioGlyco continues to drive advancements in glyco-related studies, playing a pivotal role in unlocking discoveries and understanding complex biological processes. Our technology platforms are constantly updated to meet the latest needs of our global clients. Our only goal is to provide high-quality services while saving time and effort for clients. If you are interested in our services, please contact us for more detailed information.

References

Zol-Hanlon, M.I.; Schumann, B. Open questions in chemical glycobiology. Communications chemistry. 2020, 3(1): 102. (Open Access)
Chao, Q.; et al. Recent progress in chemo-enzymatic methods for the synthesis of N-glycans. Frontiers in Chemistry. 2020, 8: 513. (Open Access)

This service is for Research Use Only, not intended for any clinical use.